Revelation Biosciences, Inc. (NASDAQ:REVB – Get Free Report) was the recipient of a significant increase in short interest during the month of October. As of October 30th, there was short interest totaling 12,792 shares, an increase of 93.7% from the October 15th total of 6,605 shares. Based on an average trading volume of 39,572 shares, the days-to-cover ratio is currently 0.3 days. Currently, 2.0% of the shares of the stock are sold short.
Revelation Biosciences Price Performance
Shares of Revelation Biosciences stock traded down $0.05 during trading on Friday, reaching $4.33. 6,579 shares of the stock traded hands, compared to its average volume of 27,757. The company has a market capitalization of $2.95 million, a price-to-earnings ratio of -0.10 and a beta of -0.13. The business has a fifty day simple moving average of $5.16 and a two-hundred day simple moving average of $7.42. Revelation Biosciences has a 52-week low of $3.08 and a 52-week high of $40.60.
Revelation Biosciences (NASDAQ:REVB – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($5.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($6.16) by $0.24. On average, research analysts predict that Revelation Biosciences will post -24.53 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Get Our Latest Stock Report on REVB
About Revelation Biosciences
Revelation Biosciences, Inc. is a clinical-stage biotechnology company focused on developing therapies that stimulate the body’s innate immune system. The company’s research is centered on immunologic treatments intended to help prevent or manage infectious and other acute diseases. Its lead development programs are based on Gemini, a proprietary toll-like receptor 4 agonist designed to activate innate immune responses. Revelation has investigated intranasal formulations, including REVTx-99, for potential use against respiratory viral infections, as well as other candidates aimed at addressing serious medical conditions such as sepsis.
See Also
- Five stocks we like better than Revelation Biosciences
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
